文献速递肝病消化道肿瘤与早癌

巨梁状-巨块型肝细胞癌:一种具有临床相关性的独特组织学亚型

Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance.
PubMed 文献 · Hepatology · 2018-05-09

研究回顾性纳入237例手术切除和284例射频消融的肝细胞癌样本,由肝脏病理专科医生复核,巨梁状-巨块型肝细胞癌(MTM-HCC)定义为以巨梁状结构(超过6个细胞厚)为主(>50%)。MTM-HCC在整体队列中占12%(手术切除样本16%,肝活检样本8.5%),是多变量分析中早期和总体复发的独立预测因素。

要点

  • MTM-HCC在整体队列中占12%(手术切除样本16%,肝活检样本8.5%)。
  • 手术系列中MTM-HCC是早期复发(HR 3.03,95%CI 1.38-6.65,P=0.006)和总体复发(HR 2.76,95%CI 1.63-4.67,P<0.001)的独立预测因素。
  • 射频消融系列中MTM-HCC是早期复发(HR 2.37,95%CI 1.36-4.13,P=0.002)和总体复发(HR 2.19,95%CI 1.35-3.54,P=0.001)的独立预测因素。

核心结论

  • MTM-HCC亚型在适合根治性治疗的患者中可靠地观察到12%,代表一种侵袭性肝细胞癌形式,可能需要更特异的治疗策略。

研究设计与样本

  • 回顾性纳入237例手术切除的肝细胞癌手术样本和284例射频消融患者的肝活检样本,由肝脏疾病专科病理医生复核组织学切片。
  • MTM-HCC亚型定义为以巨梁状结构(超过6个细胞厚)为主(>50%)。
  • 基线记录主要临床和生物学特征,临床终点为早期复发和总体复发。

主要发现

  • MTM-HCC在整体队列中占12%(手术切除样本16%,肝活检样本8.5%)。
  • MTM-HCC在基线时与已知不良预后因素相关(肿瘤大小、甲胎蛋白水平、卫星结节和血管侵犯)。
  • 多变量分析显示MTM-HCC是早期和总体复发的独立预测因素:手术系列HR 3.03(95%CI 1.38-6.65,P=0.006)和HR 2.76(95%CI 1.63-4.67,P<0.001)。
  • 射频消融系列中MTM-HCC是早期和总体复发的独立预测因素:HR 2.37(95%CI 1.36-4.13,P=0.002)和HR 2.19(95%CI 1.35-3.54,P=0.001)。
  • 按常见临床、生物学和病理侵袭性特征分层后,MTM-HCC的预后价值仍然保留;射频消融系列中无其他基线参数与复发独立相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: We recently identified a histological subtype of hepatocellular carcinoma (HCC), designated as "macrotrabecular-massive" (MTM-HCC) and associated with specific molecular features. In order to assess the clinical relevance of this variant, we investigated its prognostic value in two large series of patients with HCC treated by either surgical resection or radiofrequency ablation (RFA). We retrospectively included 237 HCC surgical samples and 284 HCC liver biopsies from patients treated by surgical resection and RFA, respectively. Histological slides were reviewed by pathologists specialized in liver disease, and the MTM-HCC subtype was defined by the presence of a predominant (>50%) macrotrabecular architecture (more than six cells thick). The main clinical and biological features were recorded at baseline. Clinical endpoints were early and overall recurrence. The MTM-HCC subtype was identified in 12% of the whole cohort (16% of surgically resected samples, 8.5% of liver biopsy samples). It was associated at baseline with known poor prognostic factors (tumor size, alpha-fetoprotein level, satellite nodules, and vascular invasion). Multivariate analysis showed that MTM-HCC subtype was an independent predictor of early and overall recurrence (surgical series: hazard ratio, 3.03; 95% confidence interval, 1.38-6.65; P = 0.006; and 2.76; 1.63-4.67; P < 0.001; RFA series: 2.37; 1.36-4.13; P = 0.002; and 2.19; 1.35-3.54; P = 0.001, respectively). Its prognostic value was retained even after patient stratification according to common clinical, biological, and pathological features of aggressiveness. No other baseline parameter was independently associated with recurrence in the RFA series. CONCLUSION: The MTM-HCC subtype, reliably observed in 12% of patients eligible for curative treatment, represents an aggressive form of HCC that may require more specific therapeutic strategies. (Hepatology 2018;68:103-112).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Ziol M, Poté N, Amaddeo G, et al. Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. Hepatology. 2018. PMID: 29281854. doi:10.1002/hep.29762

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。